Drugs / IDREVLORIDE
IDREVLORIDE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01793649 | Oct 2012 → Jun 2013 | chronic obstructive pulmonary disease, cystic fibrosis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT02871778 | Aug 2016 → Nov 2018 | primary ciliary dyskinesia | Parion Sciences | Completed | Met primary |
| Phase 2 | NCT02709109 | Feb 2016 → Sep 2017 | cystic fibrosis | Parion Sciences | Completed | Missed primary |
| Phase 2 | NCT02343445 | Apr 2015 → Feb 2016 | cystic fibrosis | Parion Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01840735 Comparator | May → Jul 2013 | cystic fibrosis | Gilead Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-25 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Third-Quarter 2017 Financial Results vrtx.com ↗
Vertex today announced results from a Phase 2, 28-day study of the inhaled epithelial sodium channel (ENaC) inhibitor, VX-371 (P-1037), being developed in collaboration with Parion Sciences. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-25 | Vertex Pharmaceuticals Incorporated | Vertex Reports Third-Quarter 2017 Financial Results vrtx.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDREVLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095031 ↗ |
| Known as | GS-560876 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095031 ↗ |
| Known as | GS-5737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01840735 ↗ |
| Known as | P-1037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02343445 ↗ |
| Known as | VRT-1499138 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095031 ↗ |
| Known as | VX-371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871778 ↗ |
| Action | Inhibit | “P-1037 is a novel ENaC inhibitor” NCT02343445 ↗ |
| Modality | Small molecule | — CHEMBL5095031 ↗ |
| Route | Inhaled | “P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID” NCT02343445 ↗ |